David Gonzalez

List of Publications by Year
in descending order

40 papers	1,646 citations	279798 23 h-index	302126 39 g-index
40 all docs	40 docs citations	40 times ranked	3739 citing authors

#	Article	IF	Citations
1	Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. Leukemia, 2019, 33, 2241-2253.	7.2	177
2	Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. Lancet, The, 2016, 388, 1002-1011.	13.7	132
3	Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood, 2013, 121, 3413-3419.	1.4	128
4	Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone. Blood, 2003, 102, 2994-3002.	1.4	101
5	Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma. British Journal of Cancer, 2017, 117, 876-883.	6.4	98
6	Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. Seminars in Oncology, 2017, 44, 187-197.	2.2	76
7	Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance. Clinical Cancer Research, 2020, 26, 608-622.	7.0	71
8	Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS. Leukemia, 2019, 33, 2254-2265.	7.2	70
9	Nextâ€generation sequencing: a change of paradigm in molecular diagnostic validation. Journal of Pathology, 2014, 234, 5-10.	4.5	68
10	High-Throughput Immunogenetics for Clinical and Research Applications in Immunohematology: Potential and Challenges. Journal of Immunology, 2017, 198, 3765-3774.	0.8	61
11	The spectrum of EWSR1-rearranged neoplasms at a tertiary sarcoma centre; assessing 772 tumour specimens and the value of current ancillary molecular diagnostic modalities. British Journal of Cancer, 2017, 116, 669-678.	6.4	48
12	TP53 Mutational Status and Cetuximab Benefit in Rectal Cancer: 5-Year Results of the EXPERT-C Trial. Journal of the National Cancer Institute, 2014, 106, .	6.3	46
13	A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. European Journal of Cancer, 2019, 121, 224-235.	2.8	44
14	Genomic landscape of platinum resistant and sensitive testicular cancers. Nature Communications, 2020, 11, 2189.	12.8	43
15	A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1029-1039.	1.1	38
16	Detection of EGFR Variants in Plasma. Journal of Molecular Diagnostics, 2018, 20, 483-494.	2.8	37
17	Comprehensive translocation and clonality detection in lymphoproliferative disorders by next-generation sequencing. Haematologica, 2017, 102, e57-e60.	3.5	35
18	Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients. International Journal of Cancer, 2020, 146, 94-102.	5.1	34

#	Article	IF	Citations
19	Rare disruptive mutations in ciliary function genes contribute to testicular cancer susceptibility. Nature Communications, 2016, 7, 13840.	12.8	32
20	Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial. BMC Cancer, 2019, 19, 582.	2.6	32
21	Desmoplastic small round cell tumor: evaluation of reverse transcription-polymerase chain reaction and fluorescence in situ hybridization as ancillary molecular diagnostic techniques. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 631-640.	2.8	28
22	Diseaseâ€biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferations. Journal of Pathology, 2019, 247, 416-421.	4.5	25
23	Angiomatoid fibrous histiocytoma: comparison of fluorescence in situ hybridization and reverse transcription polymerase chain reaction as adjunct diagnostic modalities. Annals of Diagnostic Pathology, 2015, 19, 137-142.	1.3	24
24	An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice. Human Mutation, 2018, 39, 394-405.	2.5	24
25	The New EU Regulation on In Vitro Diagnostic Medical Devices: Implications and Preparatory Actions for Diagnostic Laboratories. HemaSphere, 2021, 5, e568.	2.7	22
26	A novel next generation sequencing approach to improve sarcoma diagnosis. Modern Pathology, 2020, 33, 1350-1359.	5.5	20
27	Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. Journal of Pathology: Clinical Research, 2021, 7, 311-325.	3.0	19
28	Homologous recombination repair deficiency (HRD): From biology to clinical exploitation. Genes Chromosomes and Cancer, 2021, 60, 299-302.	2.8	16
29	Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours. Oncotarget, 2017, 8, 112036-112050.	1.8	16
30	Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. Carcinogenesis, 2016, 37, 852-857.	2.8	15
31	HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee. Journal of Clinical Pathology, 2018, 71, 388-394.	2.0	14
32	The impact of <scp>SAMHD1</scp> expression and mutation status in mantle cell lymphoma: An analysis of the <scp>MCL</scp> Younger and Elderly trial. International Journal of Cancer, 2021, 148, 150-160.	5.1	10
33	Relevance of TP53 for CLL diagnostics. Journal of Clinical Pathology, 2019, 72, 343-346.	2.0	10
34	Ancillary molecular analysis in the diagnosis of soft tissue tumours: reassessment of its utility at a specialist centre. Journal of Clinical Pathology, 2016, 69, 505-510.	2.0	9
35	Evaluation of the optimal provision of formalin-fixed, paraffin-embedded material for reverse transcription-PCR in soft-tissue tumour diagnosis. Journal of Clinical Pathology, 2017, 70, 20-24.	2.0	9
36	Detection of Structural Variants in Circulating Cell-Free DNA from Sarcoma Patients Using Next Generation Sequencing. Cancers, 2020, 12, 3627.	3.7	7

#	Article	IF	Citations
37	Gastrointestinal Stromal Tumor With Multiple Primary Tyrosine Kinase Mutationsâ€"Clinicopathologic and Molecular Characterization. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 461-465.	1.2	4
38	Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders. Blood Advances, 2021, 5, 3188-3198.	5.2	2
39	NUQA: Estimating Cancer Spatial and Temporal Heterogeneity and Evolution through Alignment-Free Methods. Molecular Biology and Evolution, 2019, 36, 2883-2889.	8.9	1
40	Targeted Next Generation Sequencing Improves Diagnosis in Unclassifiable Leukemic Indolent B-Cell Non-Hodgkin Lymphoma and Identifies a Subset with Recurrent MYD88 Mutations in a Prospective Multicentre Study. Blood, 2020, 136, 12-13.	1.4	0